Horne McDonald K, Inkellis Elizabeth
Hematology Service, Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD 20892, USA.
Support Care Cancer. 2004 Apr;12(4):278-81. doi: 10.1007/s00520-004-0592-7. Epub 2004 Feb 13.
Because central venous catheters often become blocked by clot at their tip despite heparin flushes, a more effective anticoagulant is needed. We hypothesize that lepirudin, a recently introduced protein anticoagulant, might be more effective than heparin because of its tendency to adsorb to silicone, a commonly used catheter material. We preliminarily tested this hypothesis in vitro by measuring residual lepirudin and heparin activity at the tip of a catheter that had been submerged in a flowing stream of water for various periods of time. We observed that lepirudin is less readily removed than heparin from the catheter by fluid washing over it. This "slow-release" property of lepirudin might provide prolonged protection against clot formation at the catheter tip. A clinical trial will be necessary, however, to determine whether this property translates into significant improvement in catheter function.
尽管使用肝素冲洗,中心静脉导管仍常常在其尖端被血凝块堵塞,因此需要一种更有效的抗凝剂。我们推测,近来引入的蛋白质抗凝剂水蛭素,可能比肝素更有效,因为它易于吸附到常用的导管材料硅胶上。我们通过测量一根浸没在流动水流中不同时间段的导管尖端的残余水蛭素和肝素活性,在体外初步检验了这一推测。我们观察到,与肝素相比,水蛭素通过流体冲洗从导管上更不易被清除。水蛭素的这种“缓释”特性可能为导管尖端提供延长的抗血凝块形成保护。然而,需要进行一项临床试验来确定这种特性是否能转化为导管功能的显著改善。